Epilepsy | Unmet Need | Lennox-Gastaut Syndrome | US/EU | 2022
Lennox-Gastaut syndrome (LGS) is a severe pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities. Only a handful of antiepileptic drugs (AEDs), including Epidiolex (cannabidiol), rufinamide, clobazam, and, most recently, Fintepla (fenfluramine), are approved for the adjunctive treatment of LGS, but certain other AEDs (e.g., levetiracetam) remain a frequent off-label choice for LGS treatment. Moreover, most patients do not achieve complete seizure control with currently available AEDs, even when prescribed concomitantly. Understanding the drivers of clinical decision-making in LGS, prescribers’ perception of current treatment options, and areas of remaining unmet need will help drug developers optimize the positioning and differentiation of new products.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in LGS?
- What attributes drive decision-making in LGS, which have limited impact, and which are hidden opportunities?
- How do key agents (e.g., Epidiolex, clobazam, rufinamide) perform on queried attributes?
- What are the prevailing areas of unmet need and opportunity in LGS?
- Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and prices are acceptable to neurologists for a hypothetical new LGS drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in April 2022.
Key companies: GW Pharmaceuticals, Zogenix, Eisai, UCB Pharmaceuticals
Key drugs: Epidiolex / Epidyolex, Fintepla, rufinamide, clonazepam, lamotrigine, topiramate, levetiracetam
